Neurogene Inc. Common Stock NGNE
i
Market datapartial · fetched 2026-11-12T02:40:55.369Z
Delta surfaceAlpaca · derived absolute-delta buckets · 2026-11-20
Calculation methodologyOptions historyIV: ThetaData historical Greeks, equal-weight mean of call/put 50-delta IV across the next four listed Friday-cycle expirations, including holiday shifts verified against ThetaData’s market calendar. Missing inputs leave gaps. Skew: equal-weight mean of put minus call IV across those four expirations. IV-implied move history: mean of each expiration’s average call/put IV multiplied by the square root of remaining calendar days divided by 365.25; percentage of spot, not a quoted straddle premium.
History dataPriceAlpaca · sip · 2026-11-11T21:00:00.338428624Z
FundamentalsAlpha Vantage · unavailable
Neurogene Inc. Common Stock options
Table
| Delta | Calls | Puts | ||||
|---|---|---|---|---|---|---|
| Pseudo strike | IV | B/E move | Pseudo strike | IV | B/E move | |
| 20Δ | 17.99 | 406.5% | 38.1% | |||
| 25Δ | 20.28 | 322.9% | 29.0% | |||
| 30Δ | 47.24 | 460.5% | 98.0% | 21.97 | 265.4% | 22.2% |
| 35Δ | ||||||
| 40Δ | 29.53 | 230.6% | 26.0% | |||
| 45Δ | 28.08 | 206.2% | 20.7% | 25.01 | 133.4% | 8.4% |
| 50Δ | 26.63 | 181.8% | 15.3% | 25.55 | 127.7% | 7.5% |
| 55Δ | 25.18 | 157.5% | 10.0% | 26.10 | 122.0% | 6.6% |
| 60Δ | 24.47 | 145.3% | 8.0% | 26.64 | 116.3% | 5.7% |
| 65Δ | 23.88 | 134.7% | 6.4% | 27.19 | 110.5% | 4.9% |
| 70Δ | 23.28 | 124.2% | 4.8% | 27.73 | 104.8% | 4.0% |
| 75Δ | 22.68 | 113.6% | 3.2% | 28.28 | 99.1% | 3.1% |
| 80Δ | 21.71 | 120.4% | 2.3% | 28.82 | 93.4% | 2.3% |
20Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 17.99
- IV
- 406.5%
- B/E move
- 38.1%
25Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 20.28
- IV
- 322.9%
- B/E move
- 29.0%
30Δ
- Pseudo strike
- 47.24
- IV
- 460.5%
- B/E move
- 98.0%
- Pseudo strike
- 21.97
- IV
- 265.4%
- B/E move
- 22.2%
35Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- IV
- B/E move
40Δ
- Pseudo strike
- 29.53
- IV
- 230.6%
- B/E move
- 26.0%
- Pseudo strike
- IV
- B/E move
45Δ
- Pseudo strike
- 28.08
- IV
- 206.2%
- B/E move
- 20.7%
- Pseudo strike
- 25.01
- IV
- 133.4%
- B/E move
- 8.4%
50Δ
- Pseudo strike
- 26.63
- IV
- 181.8%
- B/E move
- 15.3%
- Pseudo strike
- 25.55
- IV
- 127.7%
- B/E move
- 7.5%
55Δ
- Pseudo strike
- 25.18
- IV
- 157.5%
- B/E move
- 10.0%
- Pseudo strike
- 26.10
- IV
- 122.0%
- B/E move
- 6.6%
60Δ
- Pseudo strike
- 24.47
- IV
- 145.3%
- B/E move
- 8.0%
- Pseudo strike
- 26.64
- IV
- 116.3%
- B/E move
- 5.7%
65Δ
- Pseudo strike
- 23.88
- IV
- 134.7%
- B/E move
- 6.4%
- Pseudo strike
- 27.19
- IV
- 110.5%
- B/E move
- 4.9%
70Δ
- Pseudo strike
- 23.28
- IV
- 124.2%
- B/E move
- 4.8%
- Pseudo strike
- 27.73
- IV
- 104.8%
- B/E move
- 4.0%
75Δ
- Pseudo strike
- 22.68
- IV
- 113.6%
- B/E move
- 3.2%
- Pseudo strike
- 28.28
- IV
- 99.1%
- B/E move
- 3.1%
80Δ
- Pseudo strike
- 21.71
- IV
- 120.4%
- B/E move
- 2.3%
- Pseudo strike
- 28.82
- IV
- 93.4%
- B/E move
- 2.3%
Options history
Table
| Date | IV (%) |
|---|---|
| 91.31% | |
| 97.01% | |
| 94.24% | |
| 93.31% | |
| 96.91% | |
| 97.01% | |
| 99.59% | |
| 89.90% | |
| 94.00% | |
| 95.95% |
Biotechnology
NKTR
Nektar Therapeutics is a biopharmaceutical company. The company is headquartered in San Francisco, California with additional operations in Huntsville, Alabama and Hyderabad,…
More →NKTX
Nkarta, Inc., a clinical-stage biopharmaceutical company, develops and markets cell therapies for the treatment of cancer. The company is headquartered in South San Francisco,…
More →NMRA
Neumora Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutic treatments for brain diseases, neuropsychiatric disorders, and…
More →NRIX
Description unavailable
More →NRXP
Description unavailable
More →NRXS
NeurAxis, Inc. is a neuromodulation therapy device company in the United States. The company is headquartered in Versailles, Indiana.
More →